Verve, Eton, Ionis, scPharmaceuticals Hold Annual Stockholders Meetings

Several biotechnology companies held their annual stockholder meetings in early June 2025, with key governance decisions made including director elections and auditor appointments. Verve Therapeutics elected three directors and ratified Ernst & Young LLP as auditor, though its stock shows strong technical momentum but faces financial challenges due to unprofitability. Eton Pharmaceuticals elected a director and ratified Crowe LLP as auditor, buoyed by FDA approval of a new drug despite mixed financial performance and valuation concerns. Pharvaris announced its upcoming annual meeting, highlighting ongoing late-stage trials for oral therapies targeting bradykinin-mediated angioedema. Ionis Pharmaceuticals re-elected directors, approved executive compensation, and ratified Ernst & Young LLP as auditor, balancing financial struggles with promising product developments and earnings guidance. Finally, scPharmaceuticals elected directors, appointed RSM US LLP as auditor, and approved executive compensation, with its stock impacted by financial difficulties and technical momentum signaling caution.